



**HAL**  
open science

# Barriers to Access Multiple Sclerosis Disease-Modifying Therapies in Middle East and North Africa: A Regional Survey-Based Study

Maya Zeineddine, Farid Boumédiène, Amal Al-Hajje, Pascale Salameh, Anne Helme, Michael Thor, B. Yamout

► **To cite this version:**

Maya Zeineddine, Farid Boumédiène, Amal Al-Hajje, Pascale Salameh, Anne Helme, et al.. Barriers to Access Multiple Sclerosis Disease-Modifying Therapies in Middle East and North Africa: A Regional Survey-Based Study. 38 th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Oct 2022, AMSTERDAM, Netherlands. hal-04074126

**HAL Id: hal-04074126**

**<https://unilim.hal.science/hal-04074126v1>**

Submitted on 19 Apr 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



# Barriers to Access Multiple Sclerosis Disease-Modifying Therapies in Middle East and North Africa: A Regional Survey-Based Study

M. Zeineddine<sup>1</sup>, F. Boumediene<sup>1</sup>, A. Al-Hajje<sup>2</sup>, P. Salameh<sup>2</sup>, A. Helme<sup>3</sup>, M.G. Thor<sup>3</sup>, B. Yamout<sup>4</sup>

<sup>1</sup>Limoges University, Institut De Neurologie Tropicale, Limoges, France, <sup>2</sup>Lebanese University, Beirut, Lebanon, <sup>3</sup>Multiple Sclerosis International Federation, London, United Kingdom, <sup>4</sup>Harley Street Medical Center, Neurology Institute, Abu Dhabi, United Arab Emirates

## Background

- Multiple Sclerosis International Federation (MSIF) Atlas recorded an increase in the prevalence of multiple sclerosis (MS) in Middle-Eastern countries from 24 per 100,000 to 33 per 100,000 between 2013 and 2020.
- Moreover, epidemiological studies from the Middle East and North Africa (MENA) region showed a rising MS prevalence during the first two decades of the 21<sup>st</sup> Century.
- Despite shifting of the MENA region from low to moderately-high risk zone for MS, the management of the disease still varies markedly between different countries based on disease-modifying therapies (DMTs) availability, accessibility, and reimbursement.
- In general, introduction of novel DMTs in most MENA countries is usually delayed, as drug approval can take several months to years once approved for use by the Food and Drug Administration (FDA) or European Medicines Agency (EMA), depending on the country.

## Objective

In order to gain better understanding of treatment accessibility and explore potential common areas of need in our MENA region, we carried an in-depth analysis of the Arab region Atlas of MS data, compiled by the MSIF, focusing on accessibility to originators and off-label DMTs in each country and identifying barriers to MS treatment.

## Methods

- This is a descriptive, survey-based study whereby we extracted data collected between October 2019 and April 2020 for countries in the MENA region by the MSIF through their Atlas of MS online survey.


## Results

- 16 out of 19 countries in the MENA region were included in this study: Algeria, Egypt, Iraq, Lebanon, Libya, Morocco, Palestine Sudan, Syria, Tunisia, Yemen, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates (UAE).

### Regulatory Approval of DMTs in the MENA region

Figure 1. Percentage of MENA countries with regulatory approval for originator DMTs.


Green = High efficacy; Yellow = Moderate efficacy; Red = Low efficacy



## Conclusion


- Most MENA countries have access to DMTs, including high-efficacy DMTs.
- More than half of MENA countries report problems with treatment continuation with cost being the major barrier to treatment.
- The number of barriers to treatment correlates with the Gross National Income (GNI) per capita – richer countries have fewer barriers to treatment.
- This study highlights unequal access to treatment across the MENA region; therefore, there is an urgent need to improve access to DMTs in lower resource settings where there are barriers to improve health outcomes for patients with MS.

### Use of On- and Off-Label DMTs in the MENA region



DMTs	Algeria	Egypt	Iraq	Lebanon	Libya	Morocco	Palestine	Sudan	Syria	Tunisia	Yemen	Kuwait	Qatar	Saudi Arabia	United Arab Emirates
Albuzumab															
Natalizumab															
Ocrelizumab															
Ribavirin															
Cladribine (IV)															
Cladribine (oral)															
Dimethyl fumarate															
Fingolimod															
Siponimod															
Glatiramer acetate															
Interferon beta 1a															
Interferon beta 1b															
Peginterferon-beta 1a															
Teriflunomide															
Asatrigine															
Cyclophosphamide															
Fludarabine															
Fumaderm															
Leflunomide															
Methotrexate															
Minocycline															
Mitomycin															

### Continuous Access to DMTs after Treatment Initiation



### Barriers to Treatment

